Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
 
Feedback
Home
c19early.org COVID-19 treatment researchCannabidiolCannabidiol (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Summary of COVID-19 cannabidiol studies

Studies   Meta Analysis   Hide extended summaries

2,424 patient cannabidiol prophylaxis study: 50% fewer cases (p=0.006).
Retrospective 1,212 patients in the USA with a history of seizure-related conditions, showing patients treated with CBD100 had significantly lower incidence of COVID-19 cases compared to a matched control group. In Vitro study showing CBD inhibits SARS-CoV-2 with Vero E6 and Calu-3 cells. Mouse study showing CBD significantly inhibited viral replication in the lung and nasal turbinate. Authors note that CBD does not inhibit ACE2 expression or the main viral proteases, inhibition occurs after viral entry. Authors stress several limitations for use at this time, including purity, quality, and the formulation of products, and potential lung damage based on administration method. Authors recommend clinical trials, but do not mention the existing RCT by Crippa et al.

Jan 2022, Science Advances, https://www.science.org/doi/10.1126/sciadv.abi6110, https://c19p.org/nguyen

39,285 patient cannabidiol prophylaxis PSM study: 56% lower mortality (p<0.0001), 25% lower ventilation (p<0.0001), and 6% longer hospitalization (p=0.0009).
Retrospective 1,657,800 COVID-19 hospitalizations in the USA including 13,095 patients with cannabis use disorder, showing lower risk of mortality with cannabis use disorder. The text and Table S2 have conflicting results for mortality: 0.45 [0.36-0.57] versus 0.43 [0.34-0.55].

Jan 2023, SSRN Electronic J., https://www.ssrn.com/abstract=4336513, https://c19p.org/mannumbethrenjithlal

1,831 patient cannabidiol prophylaxis PSM study: 2% lower mortality (p=0.57), 5% lower ventilation (p=0.02), 9% lower ICU admission (p=0.02), and 3% lower need for oxygen therapy (p=0.27).
Retrospective 1,831 hospitalized COVID-19 patients in the USA, showing lower mechanical ventilation and ICU admission, but no significant difference in mortality.

Aug 2022, J. Cannabis Research, https://jcannabisresearch.biomedcentral.com/articles/10.1186/s42238-022-00152-x, https://c19p.org/shover

72,501 patient cannabidiol prophylaxis study: 3% lower mortality (p=0.73), 27% higher ICU admission (p<0.0001), and 80% higher hospitalization (p<0.0001).
Retrospective 72,501 COVID-19 patients in the USA showing cannabis use associated with higher risk of hospitalization and ICU admission.

Jun 2024, JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820235, https://c19p.org/griffith

cannabidiol prophylaxis study: 24% more cases (p=0.009).
UK Biobank retrospective showing a higher risk of COVID-19 cases with a history of cannabis use.

Jun 2022, Chronic Diseases and Translational Medicine, https://onlinelibrary.wiley.com/doi/10.1002/cdt3.38, https://c19p.org/lehrer2

13,099 patient cannabidiol prophylaxis study: 181% higher mortality (p=0.04) and 19% fewer cases (p=0.0001).
UK Biobank retrospective with 13,099 cannabis users, showing a lower risk of COVID-19 infection, however regular users had a significantly higher risk of mortality.

Mar 2022, Frontiers in Public Health, https://www.frontiersin.org/articles/10.3389/fpubh.2022.829715/abstract, https://c19p.org/huang2

800 patient cannabidiol prophylaxis study: 212% more symptomatic cases (p<0.0001) and 3% more cases (p=0.33).
Retrospective 800 e-cigarette users in the USA, showing higher risk of COVID-19 diagnosis and symptoms with cannabis use.

Mar 2022, Addictive Behaviors, https://www.sciencedirect.com/science/article/pii/S0306460321003555, https://c19p.org/merianos

91 patient cannabidiol late treatment RCT: 557% higher hospitalization (p=0.25) and 33% slower recovery (p=0.21).
RCT 105 patients recruited in an ER in Brazil, 49 treated with CBD, showing no significant differences with treatment. 300mg CBD for 14 days. For discussion see [liebertpub.com].

Oct 2021, Cannabis and Cannabinoid Research, https://www.liebertpub.com/doi/full/10.1089/can.2021.0093, https://c19p.org/crippa
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit